Related Experiment Video

Updated: Sep 2, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

583

Three-year disease-free remission in a xeroderma pigmentosum patient after adjuvant anti-PD-1 therapy

Valerie Scheer1, Oliver Schmalz2, Percy Lehmann1

  • 1Department of Dermatology, Allergology and Dermatosurgery, Helios University Hospital Wuppertal, University Witten/Herdecke, Germany.

European Journal of Cancer (Oxford, England : 1990)
|August 4, 2022
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

3.3K
A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

12.5K

Related Experiment Videos

Last Updated: Sep 2, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

583
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

3.3K
A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

12.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

Articles linked to this work by shared authors, journal, and citation graph.

Trust in skincare and topical therapies in atopic dermatitis or psoriasis: a German cross-sectional study.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026

Treatment Preferences Among Systemic Therapy-Naïve Patients with Atopic Dermatitis or Psoriasis in Germany: A Multicentre Study.

Dermatology and therapy·2025

Avapritinib reduces symptoms and mast cell burden in systemic mastocytosis.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology·2025

[Trichophyton mentagrophytes ITS genotype VIII/Trichophyton indotineae in Germany-revisit after 5 years].

Dermatologie (Heidelberg, Germany)·2025

Feasibility of evaluating AI-enabled digital symptom monitoring in metastatic patients with NSCLC receiving pembrolizumab therapy: A German single-arm observational pilot study.

Digital health·2025

Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial.

Blood neoplasia·2025

Combined pharmacologic and lifestyle intervention for breast cancer prevention: Results of the randomized phase II TOLERANT trial in high-risk women.

European journal of cancer (Oxford, England : 1990)·2026

Systemic inflammation and patient-reported quality of life as combined prognosticators in patients with solid tumors.

European journal of cancer (Oxford, England : 1990)·2026

Analysis of quality-adjusted time without symptoms or toxicity (Q-TWiST) in patients with metastatic hormone-sensitive prostate cancer from the ARASENS trial.

European journal of cancer (Oxford, England : 1990)·2026

Lazertinib plus pemetrexed and carboplatin in patients with EGFR-mutant advanced non-small cell lung cancer after progression on lazertinib.

European journal of cancer (Oxford, England : 1990)·2026

First-line fluoropyrimidine- versus gemcitabine-based chemotherapy for metastatic recurrence after resection of ampullary adenocarcinoma: A real-world analysis of the FFCD-AC cohort.

European journal of cancer (Oxford, England : 1990)·2026

Survival benefit of recurrence-focused treatment after surgery for pancreatic ductal adenocarcinoma: A propensity score matched analysis of patients from a Dutch National and US institutional cohort.

European journal of cancer (Oxford, England : 1990)·2026

Planar Super-Oscillation Diffractive Lenses: Practical Developments and Applications.

Nanophotonics (Berlin, Germany)·2026

Experimental and Computational Investigations of Surface Polaritons at Metal-Oxide-Semiconductor Interfaces.

Nanophotonics (Berlin, Germany)·2026

Decoupled Spectral Tuning and Polarization Locking in Twisted α -MoO3 Polaritonic Crystals.

Nanophotonics (Berlin, Germany)·2026

Polymer-bridging energy transfer enables full-color erasable room-temperature phosphorescence with high stability in aqueous environments.

Chemical science·2026

Fabrication of end-coated fibre-optic ultrasound transmitters.

Biomedical optics express·2026

Hyperspectral imaging photoplethysmography: insights into the signals' origin and usage.

Biomedical optics express·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us